Journal of the Neurological Sciences
Volume 208, Issue 1 , Pages 9-15 , 15 April 2003

Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(−)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease

  • Hiroyuki Kato

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. Tel.: +81-22-717-7189; fax: +81-22-717-7192.
    • Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
    • Department of Neuroendovascular Therapy, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
    • ,
  • Tsutomu Araki

      Affiliations

    • Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Science and Medicine, Sendai, Japan
    • ,
  • Yutaka Imai

      Affiliations

    • Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Science and Medicine, Sendai, Japan
    • ,
  • Akira Takahashi

      Affiliations

    • Department of Neuroendovascular Therapy, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
    • ,
  • Yasuto Itoyama

      Affiliations

    • Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan

Received 29 April 2002 ,Revised 16 October 2002 ,Accepted 16 October 2002.

References 

  1. Araki T, Kumagai T, Tanaka K, Matsubara M, Kato H, Itoyama Y, et al.  Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res. 2001;918:176–181
  2. Brightman M. Implication of astroglia in the blood–brain barrier. Ann. N.Y. Acad. Sci. 1991;633:343–347
  3. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 1983;80:4546–4550
  4. Francis JW, von Visger J, Markelonis GJ, Oh TH. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol. Teratol. 1995;17:7–12
  5. Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 1984;224:1451–1453
  6. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 1984;311:467–469
  7. Gluck MR, Krueger MJ, Ramsey RR, Sabin SO, Singer TP, Nicklas WJ. Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridium and 4-phenylpyridine analogs in inner membrane preparation. J. Biol. Chem. 1994;269:3167–3174
  8. Kagamiishi Y, Tateishi N, Shintaku K, Satoh S, Katsumata S, Shinagawa R, et al.  Ameliorative effects of ONO-2506 on brain damage following the transient ischemia in rats. Abstr. Soc. Neurosci. 1998;24:984
  9. Kato H, Kogure K, Araki T, Itoyama Y. Astroglial and microglial reactions in the gerbil hippocampus with induced ischemic tolerance. Brain Res. 1994;664:69–76
  10. Katsumata S, Tateishi N, Kagamiishi Y, Shintaku K, Hayakawa T, Shimoda T, et al.  Inhibitory effect of ONO-2506 on GABAA receptor disappearance in cultures astrocytes and ischemic brain. Abstr. Soc. Neurosci. 1999;25:2108
  11. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979–980
  12. Matsui T, Tateishi N, Kagamiishi Y, Satoh S, Kondo K, Morioka E, et al.  Protective effects of ONO-2506 on neurological deficits and brain infarct volume following 1 week of permanent occlusion of middle cerebral artery in rats. Abstr. Soc. Neurosci. 1998;24:254
  13. Nawashiro H, Brenner M, Fukui S, Shimada K, Hallenbeck JM. High susceptibility to cerebral ischemia in GFAP-null mice. J. Cereb. Blood Flow Metab. 2000;20:1040–1044
  14. Nicholls D, Attwell D. The release and uptake of excitatory amino acids. Trends Pharmacol. Sci. 1990;11:462–468
  15. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985;36:2503–2508
  16. O'Callaghan JP, Miller DB, Reinhard JF. Characterization of the origins of astrocyte response to injury using the 1-methyl-4-phenyl-1,2,3,6-tetrahtdropyridine. Brain Res. 1990;521:3–80
  17. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20:507–577
  18. Shimoda T, Tateishi N, Shintaku K, Yada N, Katagi J, Akiyama T, et al.  ONO-2506, a novel astrocyte modulating agent, suppresses the increase of COX-2 and iNOS mRNA expression in cultured astrocytes and ischemic brain. Abstr. Soc. Neurosci. 1998;24:984
  19. Shinagawa R, Tateishi N, Shimoda T, Shintaku K, Yada N, Honjo K, et al.  ONO-2506 ameliorates neurodegeneration through inhibition of reduction of GLT-1 expression. Abstr. Soc. Neurosci. 1998;24:984
  20. Shinagawa R, Tateishi N, Shimoda T, Maekawa H, Yada N, Akiyama T, et al.  Modulating effects of ONO-2506 on astrocytic activation in cultured astrocytes from rat cerebrum. Abstr. Soc. Neurosci. 1999;25:2108
  21. Shintaku K, Tateishi N, Kagamiishi Y, Sato S, Katsumata S, Nakayama Y, et al.  Ameliorative effects of ONO-2506 on neurological deficits and infarction after transient MCA occlusion in rats: studying of therapeutic time window. Abstr. Soc. Neurosci. 1999;25:2108
  22. Tanaka S, Suzuki K, Watanabe M, Matsuda A, Tone S, Koike T. Upregulation of a new microglial gene, mrf-1, in response to programmed neuronal cell death and degeneration. J. Neurosci. 1998;18:6358–6369
  23. Tanji H, Araki T, Nagasawa H, Itoyama Y. Differential vulnerability of dopamine receptors in the mouse brain treated by MPTP. Brain Res. 1999;824:224–231
  24. Tateishi N, Mori T, Kagamiishi Y, Satoh S, Katsube N, Morikawa E, et al.  Astrocytic activation and delayed infarct expansion following permanent focal ischemia in rats: Part II. Suppression of astrocytic activation by a novel agent (R)-(−)-2propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurological deficits. J. Cereb. Blood Flow Metab. 2002;22:723–734
  25. Turski L, Bressler K, Rettig KJ, Löschmann PA, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-d-aspartate antagonists. Nature. 1991;349:414–418
  26. Walz W. Role of glial cells in the regulation of the brain ion microenvironment. Prog. Neurobiol. 1989;33:309–333
  27. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al.  Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002;22:1763–1771

PII: S0022-510X(02)00411-2

doi: 10.1016/S0022-510X(02)00411-2

Journal of the Neurological Sciences
Volume 208, Issue 1 , Pages 9-15 , 15 April 2003

Article Tools

* Image Usage & Resolution